Webinar On Demand

Multi-modal Assessment of Cardiotoxicity In Vitro Using Human Relevant Cardiomyocytes as part of an Integrated Workflow

Cardiomyocyte excitation-contraction coupling involves a number of intricately choreographed biochemical, electrophysiological and morphological events culminating in physical beating of cardiomyocytes. It is imperative that frontline in vitro cell based screens are designed in a manner that is comprehensive and able to assess cardiotoxicity from multiple perspectives, including integrated ion channel activity, calcium dynamics, contractility and viability. In this webinar we will discuss how the xCELLigence real-time cell analysis instruments including Cardio, CardioECR, ePacer and eSight can be used in conjunction with human induced pluripotent stem cell derived cardiomyocytes within an integrated workflow to assess compound-mediated cardiotoxicity in the context of :

Calcium dynamics
Contractility and inotropy
Viability and structural integrity

Presenters

Yama A. Abassi, Ph.D.

Head of Business and Assay Development, Cell Analysis, Agilent Technologies

Xiaoyu Zhang, Ph.D.

Sr. Research Scientist, Cell Analysis, Agilent Technologies

Your Personal Data

* This field is required

First Name*

Last Name*

Company/Org*

Address*

City*

State/Province

Postal Code*

Country*

Language

Phone*

Email Address*

Are you an xCELLigence user?

Yes

No

What endpoints are used for your hiPSC cardiomyocyte research?

I would like to be contacted by an Agilent representative

For Research Use Only. Not for use in diagnostic procedures

Webinar On Demand:

Multi-modal Assessment of Cardiotoxicity In Vitro Using Human Relevant Cardiomyocytes as part of an Integrated Workflow

Multi-modal Assessment of Cardiotoxicity In Vitro Using Human Relevant Cardiomyocytes as part of an Integrated Workflow

Presenters

Yama A. Abassi, Ph.D.

Xiaoyu Zhang, Ph.D.

Your Personal Data